Patent application number | Description | Published |
20100151463 | Method for Determining the Likelihood of Response to HER2 Inhibitors - The present disclosure provides methods for determining the HER2 Status of a cancer tumor sample. | 06-17-2010 |
20100209920 | Gene Expression Profiling in Biopsied Tumor Tissues - The invention concerns sensitive methods to measure mRNA levels in biopsied tumor tissues, including archived paraffin-embedded biopsy material. The invention also concerns breast cancer gene sets important in the diagnosis and treatment of breast cancer, and methods for assigning the most optimal treatment options to breast cancer patient based upon knowledge derived from gene expression studies. | 08-19-2010 |
20100222229 | Gene Expression Markers for Breast Cancer Prognosis - The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of breast cancer. | 09-02-2010 |
20110245102 | Gene Expression Profiling of EGFR Positive Cancer - The present invention concerns prognostic markers associated with EGFR positive cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed tissue samples of EGFR-expressing cancer, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor. | 10-06-2011 |
20110312532 | Gene Expression Markers for Breast Cancer Prognosis - The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of breast cancer. | 12-22-2011 |
20120178644 | GENE EXPRESSION PROFILING OF EGFR POSITIVE CANCER - The present invention concerns prognostic markers associated with EGFR positive cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed tissue samples of EGFR-expressing cancer, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor. | 07-12-2012 |
20120225433 | Gene Expression Markers for Breast Cancer Prognosis - The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of breast cancer. | 09-06-2012 |
20130196321 | Gene Expression Profile Algorithm and Test for Determining Prognosis of Prostate Cancer - The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient. | 08-01-2013 |
Patent application number | Description | Published |
20080318230 | GENE EXPRESSION MARKERS FOR RESPONSE TO EGFR INHIBITOR DRUGS - The present invention concerns prognostic markers associated with cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed samples of cancer tissue, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor. | 12-25-2008 |
20090125247 | GENE EXPRESSION MARKERS OF RECURRENCE RISK IN CANCER PATIENTS AFTER CHEMOTHERAPY - The present invention relates to genes, the expression levels of which are correlated with likelihood of breast cancer recurrence in patients after tumor resection and chemotherapy. | 05-14-2009 |
20090280490 | Expression Profile Algorithm and Test for Cancer Prognosis - The present invention provides a noninvasive, quantitative test for prognosis determination in cancer patients. The test relies on measurements of the tumor levels of certain messenger RNAs (mRNAs). These mRNA levels are inserted into a polynomial formula (algorithm) that yields a numerical recurrence score, which indicates recurrence risk. | 11-12-2009 |
20090298701 | PREDICTORS OF PATIENT RESPONSE TO TREATMENT WITH EGF RECEPTOR INHIBITORS - The present invention provides methods and compositions to facilitate determining whether an EGFR-expressing cancer in an individual is an EGFR inhibitor-responsive cancer, as well as methods for determining the likelihood that a patient having an EGFR-expressing cancer will exhibit a beneficial response to an EGFR inhibitor therapy. The methods generally involve determining a normalized expression level of a gene product that correlates with EGFR inhibitor responsiveness. | 12-03-2009 |
20100184041 | Molecular Indicators of Breast Cancer Prognosis and Prediction of Treatment Response - The present invention relates to quantitative molecular indicators that can guide clinical decisions in breast cancer, such as estrogen receptor (ESR1)-positive, lymph node-negative breast cancer. In particular, the invention concerns certain genes, the varied expression of which indicates the likelihood of recurrence of surgically resected breast cancer in patients who are not treated with a therapeutic agent in the adjuvant setting. In addition, the invention concerns the use of quantitative measurement of the expression of certain genes, including the ESR1 gene, that measure as a continuous variable, to determine (a) the likelihood of a beneficial response to the anti-estrogen therapeutic agent, such as tamoxifen; and (b) the potential magnitude of beneficial response to chemotherapy. | 07-22-2010 |
20100267032 | Prediction of Likelihood of Cancer Recurrence - The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer. | 10-21-2010 |
20100285980 | GENE EXPRESSION PROFILE ALGORITHM AND TEST FOR LIKELIHOOD OF RECURRENCE OF COLORECTAL CANCER AND RESPONSE TO CHEMOTHERAPY - Algorithm-based molecular assays that involve measurement of expression levels of prognostic and/or predictive genes, or co-expressed genes thereof, from a biological sample obtained from a cancer patient, and analysis of the measured expression levels to provide information concerning the likelihood of recurrence of colorectal cancer and/or the likelihood of a beneficial response to chemotherapy for the patient are provided herein. Methods of analysis of gene expression values of prognostic and/or predictive genes, as well as methods of identifying gene expression-tumor region ratios, tumor-associated stromal surface area, and gene cliques, i.e. genes that co-express with a validated biomarker and thus may be substituted for that biomarker in an assay, are also provided. | 11-11-2010 |
20110129833 | Gene Expression Markers for Predicting Response to Chemotherapy - The present invention provides sets of genes the expression of which is important in the prognosis of cancer. In particular, the invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial treatment response to chemotherapy. FHIT; MTA1; ErbB4; FUS; BBC3; IGF1R; CD9; TP53BP1; MUC1; IGFBP5; rhoC; RALBP1; STAT3; ERK1; SGCB; DHPS; MGMT; CRIP2; ErbB3; RAP1GDS1; CCND1; PRKCD; Hepsin; AK055699; ZNF38; SEMA3F; COL1A1; BAG1; AKT1; COL1A2; Wnt.5a; PTPD1; RAB6C; GSTM1, BCL2, ESR1; or the corresponding expression product, is determined, said report includes a prediction that said subject has a decreased likelihood of response to chemotherapy. | 06-02-2011 |
20110171633 | METHOD TO USE GENE EXPRESSION TO DETERMINE LIKELIHOOD OF CLINICAL OUTCOME OF RENAL CANCER - The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma. | 07-14-2011 |
20110171641 | Gene Expression Markers of Recurrence Risk in Cancer Patients After Chemotherapy - The present invention relates to genes, the expression levels of which are correlated with likelihood of breast cancer recurrence in patients after tumor resection and chemotherapy. | 07-14-2011 |
20110178374 | Predicting Response to Chemotherapy Using Gene Expression Markers - The present invention provides gene expression information useful for predicting whether a cancer patient is likely to have a beneficial response to treatment with chemotherapy, comprising measuring, in a biological sample comprising a breast tumor sample obtained from the patient, the expression levels of gene subsets to obtain a risk score associated with a likelihood of a beneficial response to chemotherapy, wherein the score comprises at least one of the following variables: (i) Recurrence Score, (ii) ESRI Group Score; (iii) Invasion Group Score; (iv) Proliferation Group Score; and (v) the expression level of the RNA transcript of at least one of MYBL2 and SCUBE2, or the corresponding expression product. The invention further comprises a molecular assay-based algorithm to calculate the likelihood that the patient will have a beneficial response to chemotherapy based on the risk score. | 07-21-2011 |
20110287958 | Method for Using Gene Expression to Determine Colorectal Tumor Stage - The invention relates to methods of determining a colorectal tumor stage in a patient by gene expression analysis. The method comprises assaying the level of at least one RNA transcript, or its expression product, which is correlated to colorectal tumor stage. The invention may be useful for determining whether a patient has stage II or stage III colorectal cancer. | 11-24-2011 |
20120028264 | METHOD FOR USING GENE EXPRESSION TO DETERMINE PROGNOSIS OF PROSTATE CANCER - Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein. | 02-02-2012 |
20140287421 | GENE EXPRESSION MARKERS FOR BREAST CANCER PROGNOSIS - The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of breast cancer. | 09-25-2014 |
20140303002 | Gene Expression Profile Algorithm and Test for Determining Prognosis of Prostate Cancer - The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient. | 10-09-2014 |
20150079591 | PREDICTING RESPONSE TO CHEMOTHERAPY USING GENE EXPRESSION MARKERS - The present invention provides gene expression information useful for predicting whether a cancer patient is likely to have a beneficial response to treatment with chemotherapy, comprising measuring, in a biological sample comprising a breast tumor sample obtained from the patient, the expression levels of gene subsets to obtain a risk score associated with a likelihood of a beneficial response to chemotherapy, wherein the score comprises at least one of the following variables: (i) Recurrence Score, (ii) ESRI Group Score; (iii) Invasion Group Score; (iv) Proliferation Group Score; and (v) the expression level of the RNA transcript of at least one of MYBL2 and SCUBE2, or the corresponding expression product. The invention further comprises a molecular assay-based algorithm to calculate the likelihood that the patient will have a beneficial response to chemotherapy based on the risk score. | 03-19-2015 |